SEARCH

SEARCH BY CITATION

References

  • 1
    Barber H, Graber E. The postmenopausal palpable ovary syndrome. Obstet Gynecol 1971; 38: 921.
  • 2
    Berek J, Hacker N. Practical gynecologic oncology. Baltimore: Williams and Wilkins, 1989: 328.
  • 3
    Finkler NJ, Benacerraf B, Lavin PT, Wojciechowski C, Knapp RC. Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses. Obstet Gynecol 1988; 72: 65964.
  • 4
    Gaducci A, Capriello P, Ferdeghini M, Madrigali A, Puccetti A, Annicchiarico C, et al. Pelvic ultrasound, serum CA 125 assay, CA 19.9 assay and serum CA 72. 4 assay in the differential diagnosis of ovarian masses. Cancer J 1991; 4: 24953.
  • 5
    Rulin MC, Preston AL. Adnexal masses in postmenopausal women. Obstet Gynecol 1987; 70: 57881.
  • 6
    Meire HB, Farrant P, Guha T. Distinction of benign from malignant ovarian cysts by ultrasound. Br J Obstet Gynaecol 1978; 85: 8939.
  • 7
    Hermann UJ Jr., Locher GW, Goldhirsch A. Sonographic patterns of ovarian tumors: prediction of malignancy. Obstet Gynecol 1987; 69: 777.
  • 8
    Andolf E, Jdrgensen C, Astedt B. Ultrasound examination for detection of ovarian carcinoma in risk groups. Obstet Gynecol 1990; 1069.
  • 9
    Andolf E, Jcirgensen C. A prospective comparison of clinical ultrasound and operative examination of the female pelvis. J Ultrasound Med 1988; 7: 61720.
  • 10
    Andolf E, Jøgensen C. Simple adnexal cysts diagnosed by ultrasound in postmenopausal woen. J Clin Ultrasound 1988; 16: 3013.
  • 11
    Benacerraf BR, Finkler N, Wojciechowski C, Knapp RC. Sonographic accuracy in the diagnosis of ovarian masses. J Reprod Med 1990; 35: 4915.
  • 12
    Tay SK, Tan YY. Risk factors and a risk scoring system for the prediction of malignancy in ovarian cysts. Austr NZ J Obstet Gynaecol 1992; 32: 3415.
  • 13
    Bast R, Klug T, St. John E, Jenison E, Niloff J, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309883.
  • 14
    Klug T, Bast R, Niloff J, Knapp R, Zurawski V. A monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res 1984; 44: 1048.
  • 15
    Kenemans P, Yedema CA, Bon GG, von Mensdorff-Pouilly S. CA 125 in gynecological pathology: a review. Eur J Obstet Gynecol Reprod Biol 1993; 49: 11524.
  • 16
    Jacobs I, Bast RC. The CA 125 tumor-associated antigen: a review of the literature. Hum Reprod 1989; 4: 112.
  • 17
    Einhorn N, Bast RC, Knapp RC, Tjenberg B, Zurawski V. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol 1986; 67: 414.
  • 18
    O'Connell G, Ryan E, Murphy J, Prefontaine M. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses. Obstet Gynecol 1987; 70: 930.
  • 19
    Vasilev SA, Schlaerth JB, Campeau J, Morrow CP. Serum CA 125 levels in preoperative evaluation of pelvic masses. Obstet Gynecol 1988; 71: 7516.
  • 20
    Di-Xia C, Schwartz P, Xinguo L, Zhan Y. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol 1988; 72: 237.
  • 21
    Yedema C, Massuger L, Hilgers J, Servaas J, Poels L, Thomas C, et al. Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA 125 and CA 15.3 serum assays. Int J Cancer 1988; 3 (Suppl): 617.
  • 22
    Mastropaolo W, Fernandez Z, Miller EL. Pronounced increase in the concentration of an ovarian tumor marker, CA 125, in serum of a healthy subject during menstruation. Clin Chem 1986; 32: 2110.
  • 23
    Pittaway DE, Fayez JA. Serum CA 125 antigen levels increase during menses. Am J Obstet Gynecol 1987; 156: 75.
  • 24
    Haga Y, Sakamoto K, Egami H. Evaluation of serum CA 125 values in healthy individuals and pregnant women. Am J Med Sci 1986; 292: 25.
  • 25
    Pittaway DE, Fayez JA. The use of CA 125 in the diagnosis and management of endometriosis. Fertil Steril 1986; 46: 790.
  • 26
    Niloff JM, Knapp RC, Schaetzl E, Reynolds C, Bast RC Jr. CA 125 antigen levels in ocstetric and gynecologic patients. Obstet Gynecol 1984; 64: 7037.
  • 27
    Zurawski V, Broderick S, Pickens P, Knapp R. Serum CA 125 levels in a group of non-hospitalized women: relevance for the early detection of ovarian cancer. Obstet Gynecol 1987; 69: 60611.
  • 28
    Zurawski V, Sjovall K, Schoenfeld D, Broderick S, Hall P, Bast R, et al. Prospective evaluation of serum CA 125 levels in a normal population, phase 1: the specificities of single and serial deter-minations in testing for ovarian cancer. Gynecol Oncol 1990; 36: 299305
  • 29
    Verstraeten A, Kenemans P, Bon G, van Kamp G, Hilgers J. Age related normal levels (cut-off values) of seven common tumor markers. [abstract]. J Tumor Marker Oncol 1992; 7: 81.
  • 30
    Yedema C, Kenemans P, Wobbes Th, Thomas C, Bon G, Mulder C, et al. The use of tumor markers in the differential diagnosis between ovarian and colorectal carcinoma. Tumor Bid 1992d; 13: 1826.
  • 31
    Grover S, Quinn M, Weideman P, Koh H. Factors influencing serum CA 125 levels in normal women. Obstet Gynecol 1992; 79: 5114.
  • 32
    Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988; 240: 128593.
  • 33
    Gardner MJ, Altman DG. Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J 1986; 292: 74650.
  • 34
    Ciba-Geigy Ltd, editors. Wissenschaftliche Tabellen Geigy. Teilband Statistik. 8th ed. Basel, Switzerland: Ciba-Geigy, 1980.
  • 35
    Buist MR, Kenemans P, Vermorken JB, Goldingh RP, Burger CW, den Hollander W, et al. Radioimmunotargeting in ovarian caranoma patients with indium-111 labeled monoclonal antibody OV-TL 3 F(ab')2: pharmacokinetics, tissue distribution, and tumor imaging. Int J Gynecol Cancer 1992; 2: 2334.
  • 36
    Sassone M, Timor-Tritsch I, Artner A, Westhoff C, Warren W. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 1991; 78: 706.
  • 37
    Granberg S, Norstrom A, Wikland M. Tumors in the lower pelvis as imaged by vaginal sonography. Gynecol Oncol 1990; 37: 2249.
  • 38
    Bourne T, Campbell S, Steer C, Whitehead MI, Collins WP. Transvaginal color flow imaging: a possible new screening technique for ovatian cancer. Br Med J 1989; 299: 136770.
  • 39
    Kawai M, Kano T, Kikkawa F, Maeda O, Oguchi H, Tomoda Y. Transvaginal doppler ultrasound with color flow imaging in the diagnosis of ovarian cancer. Obstet Gynecol 1992; 79: 1637.
  • 40
    Weiner Z, Thaler L, Beck D, Rottem S, Deutsch M, Brandes J. Differentiating malignant from benign ovarian tumors with transvaginal color flow imaging. Obstet Gynecol 1992; 79: 15962.
  • 41
    Schneider VL, Schneider A, Reed K, Hatch KD. Comparison of Doppler with two-dimensional sonography and CA 125 for prediction of malignancy of pelvic masses. Obstet Gynecol 1993; 81: 9838.
  • 42
    Malkasian GD Jr., Knapp RC, Lavin IT, Zurawski VR, Podratz KC, Stanhope CR, et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988; 159: 3416.
  • 43
    Zurawski V, Knapp R, Einhorn N, Kenemans P, Mortel R, Ohmi K, et al. An initial analysis of preoperative serum CA 125 in patients with early stage ovarian carcinoma. Gynecol Oncol 1988; 30: 714.
  • 44
    Inoue M, Fukita M, Nakazawa A, Ogawa H, Tanizawa O. Sialyl Tn, Sialayl-Lewis XI, CA 19.9, CA 125, carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumors. Obstet Gynecol 1992; 79: 43440.
  • 45
    Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Gruzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br. Obstet Gynaecol 1990; 97: 9229.
  • 46
    Lahousen M, Stettner H, Pickel H, Urdl W, Purstner P. The predictive value of a combination of tumor makers in monitoring patients with ovarian cancer. Cancer 1987; 60: 222832.
  • 47
    Panza N, Pacilio G, Campanella L, Peluso G, Battista C, Amoriello A, et al. Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and beta-chain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma. Cancer 1988; 61: 7683.
  • 48
    Yedema CA, Massuger L, Hilgers J, Servaas J, Poels L, Thomas C, et al. Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA 125 and CA 15.3 serum assays. Intl Cancer 1988; 3: 617.
  • 49
    Vardi JR, Tadros GH, Foemmel R, Shebes M. Plasma lipid-associated sialic acid and serum CA 125 as indicators of disease status with advanced ovarian cancer. Obstet Gynecol 1989; 74: 37983.
  • 50
    Tholander B, Taube A, Lindgren A, Sjijberg O, Stendahl U, Kiviranta A, et al. Pretreatment serum levels of CA 125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: relevance for differential diagnosis. Gynecol Oncol 1990; 39: 1625.
  • 51
    Soper JT, Hunter V, Daly L, Tanner M, Creasman WT, Bast RC. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet Gynecol 1990; 75: 24954.
  • 52
    Toftager-Larsen K, Hording U, Dreisler A, Daugaard S, Lund B, Bock J, et al. CA 125, I'lacental alkaline phosphatase and tissue polypeptide antigen as preoperative serum marker in ovarian carcinoma. Gynecol ObstetInvest 1992; 33: 17782.
  • 53
    O'Connell G, Ryan E, Murphy J, Prefontaine M. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses. Obstet Gynecol 1987; 70: 930.
  • 54
    de Crespigny LCh, Robinson HP, Davoren RAM, Fortune D. The “simple” ovarian cyst: aspirate or operate? Br J Obstet Gynaecol 1989; 96: 10359.
  • 55
    Parker WH, Berek JS. Management of selected cystic adnexal masses in postmenopausal women by operative laparoscopy: a pilot study. Am Obstet Gynecol 1990; 163: 15747.
  • 56
    Maiman M, Seltzer V, Boyce J. Laparoscopic excision of ovarian neoplasms subsequently found to be malignant. Obstet Gynecol 1991; 77: 5635.
  • 57
    Nezhat F, Nezhat C, Welander CE, Benigno B. Four ovarian cancers diagnosed during laparoscopic management of 1011 women with adnexal masses. Am J Obstet Gynecol 1992; 167: 7906.